513 results on '"Haanen, J"'
Search Results
2. Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
3. Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit
4. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
5. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial
6. Immuun- en targeted therapie
7. Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
8. Huidtumoren
9. Immunotherapie van kanker
10. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
11. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
12. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
13. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
14. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
15. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
16. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
17. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
18. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
19. Gender medicine and oncology: report and consensus of an ESMO workshop
20. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
21. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
22. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
23. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort
24. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
25. Immunotherapie van kanker
26. Cryoablation and immunotherapy: an overview of evidence on its synergy
27. One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
28. Additional file 1 of Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial
29. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
30. DNA Vaccines and Intradermal Vaccination by DNA Tattooing
31. MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
32. Real-World data of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place
33. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
34. T006 Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD1 monotherapy in advanced melanoma
35. The development of a flexible and easy to tailor disease model to estimate the outcomes of treatment sequences in advanced melanoma by combining trial and real-world data
36. Health state utilities of advanced melanoma patients treated in clinical practice in the era of novel immuno- and targeted therapies
37. Quality of life in advanced melanoma patients in the era of novel immuno- and targeted therapies
38. Validity of the eq-5d-3l and eq-5d-5l in advanced melanoma
39. Clinical Pharmacokinetics of Vemurafenib in BRAF‐Mutated Melanoma Patients
40. Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines
41. The impact of COVID-19 on oncology professionals – one year on: lessons learned from the ESMO Resilience Task Force survey series
42. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
43. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
44. LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors
45. Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors
46. Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study
47. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma
48. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer☆
49. An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)
50. Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.